NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Eikon Therapeutics, Inc. (EIKN) Stock Analysis

Eikon Therapeutics, Inc. (EIKN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

EIKN

$8.00

−$0.18 (−2.20%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare EIKN with… →

EIKN Key Statistics

As of Oct 21, 2026
Trading
Open
$8.12
Previous Close
$8.18
Day's Range
7.97–8.40
52-Week Range
6.45–17.40
Volume
240.64K
Valuation
Market Cap
$433.32M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−8.51
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$324.25M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
54.17M
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
525.39K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

Eikon Therapeutics, Inc. (EIKN) has a market capitalization of $433.32M.

In fiscal 2025, EIKN reported revenue of $0.00.

EIKN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$324.25M—
2024$0.00−$243.81M—
2023$0.00−$242.00M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$338.95M−$324.25M—
2024$0.00—−$260.34M−$243.81M—
2023$0.00—−$265.74M−$242.00M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 11 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Eikon Therapeutics, Inc. (EIKN) is capitalised at $433.32M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 384 employees.

The 52-week range on file runs from $6.45 to $17.40. EIKN last closed at $8.00 on October 21, 2026. That is −$0.18 (−2.20%) against the previous close. The latest close sits 24.03% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $324.25M. Trailing earnings per share are −8.51.

Across the 3 fiscal years on file, revenue moves from $0.00 in 2023 to $0.00 in 2025. Of those 3 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The stored price history starts on February 5, 2026, and the total return since then is −46.67%.

Growth & Income

No dividend is on file for EIKN.

2026 is still running; the total return is −46.67% year to date.

Peer Comparison

Eikon Therapeutics, Inc. (EIKN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Eikon Therapeutics, Inc. EIKN $433.32M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Eikon Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Eikon Therapeutics, Inc.

Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.

Visit website →